Financial Report: Baxalta

Baxalta

1Q Revenues: $1.5 billion (+10%)

1Q Earnings: $145 million (-47%)

Comments: Global hematology revenues were $843 million, up 8%. Growth was driven by the U.S. introduction of ADYNOVATE, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, as well as heightened demand for ADVATE. Immunology sales were $653 million up 13% (excluding the impact of foreign exchange). Baxalta’s new oncology business recorded sales of $52 million in the quarter, reflecting revenues of ONCASPAR, a biologic for acute lymphoblastic leukemia (ALL). Baxalta separated from Baxter International July 1, 2015.